Bioventus Inc. reported $582M of revenue over the trailing twelve months, +3.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $582M (to Q2 2026). Net income: $54M, trailing twelve months to Q2 2026. Free cash flow: $94M, trailing twelve months to Q2 2026. Operating margin: 9.8%, trailing twelve months to Q2 2026.

BVSBioventus Inc.

Healthcare

$12.70+91% 1Y

$12.70

$6.5152 weeks$15.30

BVS as reported

Bioventus Inc. reported $582M of revenue over the trailing twelve months, +3.1% on the year before. 11 reported series are charted on this page, each one as filed.

$582M

Revenue, trailing twelve months · to Q2 2026 · +3.1% against the twelve months before

Net income: $54M
Net income · −7551% year on year · trailing twelve months to Q2 2026
Free cash flow: $94M
Free cash flow · +177% year on year · trailing twelve months to Q2 2026
Operating margin: 9.8%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BVS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$582M	+3.1%	Q2 2026
Net income	$54M	−7551%	Q2 2026
EPS	$0.77	−7800%	Q2 2026
Gross margin	69%	n/a	Q2 2026
Operating margin	9.8%	n/a	Q2 2026
Net margin	9.0%	n/a	Q2 2026
ROE	14%	n/a	Q2 2026
ROA	4.2%	n/a	Q2 2026
ROIC	9.6%	n/a	Q2 2026
Free cash flow	$94M	+177%	Q2 2026
P/E	16.5	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.